Related Experiment Video

Updated: Aug 15, 2026

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors
12:03

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors

Published on: June 7, 2016

Angiotensin receptor blockers in congestive heart failure: evidence, concerns, and controversies

Vishal Bhatia1, Ruchi Bhatia, Boban Mathew

  • 1Department of Internal Medicine, State University of New York, Buffalo, NY 14216, USA. vbhatia@buffalo.edu

Cardiology in Review
|October 19, 2005
PubMed

Insights

Angiotensin receptor blockers (ARBs) may offer benefits in congestive heart failure (CHF) by directly blocking angiotensin II (ATII) receptors, potentially overcoming limitations of ACE inhibitors in managing this condition.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Heart failure involves neurohormonal activation, primarily via the renin-angiotensin-aldosterone system (RAS).
  • Angiotensin II (ATII) produced by RAS activation causes adverse effects like hemodynamic and renal dysfunction, inflammation, and cardiac remodeling.
  • Angiotensin-converting enzyme inhibitors (ACEIs) mitigate ATII effects in congestive heart failure (CHF), but may not fully suppress ATII production due to RAS-independent pathways.

Purpose of the Study:

  • To evaluate the role and place of angiotensin receptor blockers (ARBs) in the therapy for CHF.
  • To compare the efficacy of ARBs against existing treatments like ACEIs in managing CHF.

Main Methods:

  • Review of multiple studies investigating the use of ARBs in CHF patients.
  • Analysis of clinical trial data to assess the impact of ARBs on CHF outcomes.

Main Results:

  • ACEIs inhibit ATII production but may not be fully effective due to alternative ATII generation pathways.
  • ARBs directly block ATII receptors, offering a potential advantage in CHF management.
  • Evidence from reviewed studies is synthesized to determine the therapeutic positioning of ARBs in CHF.

Conclusions:

  • ARBs represent a significant therapeutic option for CHF, potentially offering superior ATII blockade compared to ACEIs.
  • Further research and clinical guidelines are needed to fully define the optimal role of ARBs in comprehensive CHF treatment strategies.

More Related Videos

Ascending Aortic Constriction in Rats for Creation of Pressure Overload Cardiac Hypertrophy Model10:18

Ascending Aortic Constriction in Rats for Creation of Pressure Overload Cardiac Hypertrophy Model

Published on: June 29, 2014

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...